Alkem Labs Q1FY27 Results: Total Income ₹3,740 Crore, Net Profit ₹520 Crore
Alkem Laboratories reported Q1FY27 results. Total income was ₹3,740 crore, and net profit was ₹520 crore. Comprehensive income was ₹523 crore. Basic and diluted EPS stood at ₹43.49. The results were approved by the Board on August 14, 2026.
The financial results, particularly the decrease in net profit year-on-year, could have a moderate impact on investor sentiment and the company's stock performance.
The financial results show a mixed performance with a notable decrease in net profit compared to the previous year's quarter, while income has increased. The sentiment is neutral as there are no strong positive or negative indicators.
Alkem Laboratories Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company reported a total income from operations of ₹37,401.5 million (₹3740.15 crore) for the quarter. Net profit after tax attributable to the owners of the company stood at ₹5,199.6 million (₹519.96 crore).
The total comprehensive income for the period attributable to the owners was ₹5,228.5 million (₹522.85 crore). The company's paid-up equity share capital remained at ₹239.1 million. Earnings per share (EPS) for the quarter were ₹43.49 (basic and diluted).
The financial results were reviewed by the Audit Committee on August 13, 2026, and approved by the Board of Directors on August 14, 2026. The auditors have issued an unmodified review report on these financial results.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.